Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings

NCT07056036 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve willpower, self-control and food cravings? Participants will be asked to: * Undergo six treatments * Complete the Brief Self-control Scale * Complete the Food Cravings Questionnaire - Trait * Complete the Therapy Comfort Questionnaire * Complete the Subject Satisfaction Questionnaire

Interventions

  • DEVICE ActiveTreatment with BTL-699-2
  • DEVICE Sham Treatment with BTL-699-2

Study Locations (4)

Colorado

  • Aria Integrative Health — Denver

Florida

  • A New You Wellness — Miami

Indiana

  • Cady Wellness Institute — Newburgh

Ohio

  • Jiva Med Spa — Columbus

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2024-11-01
Est. Completion 2025-10-10
Phase NA

Sponsor

BTL Industries

9 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07056036

The ClinicalTrials.gov registry entry for NCT07056036 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BTL Industries, which has 9 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Self-Control appearing as the primary indexed condition, and to 2 interventions — of which ActiveTreatment with BTL-699-2 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07056036 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Colorado, Florida, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07056036 about?

NCT07056036 is a clinical study titled "EXOMIND (BTL-699-2) for the Improvement in Willpower & Food Cravings". The goal of this clinical trial is to evaluate if the treatment with ExoMIND (BTL-699-2) device is able to improve willpower, self-control and food cravings in adults above the age of 22 years. The main question it aims to answer is: Does the treatment with EXOMIND (BTL-699-2) device improve willpo...

What is the current status of trial NCT07056036?

This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2024-11-01. Estimated completion is 2025-10-10.

What conditions does trial NCT07056036 study?

This clinical trial studies the following conditions: Self-Control, Food Cravings. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07056036?

The interventions under investigation include: ActiveTreatment with BTL-699-2 (DEVICE), Sham Treatment with BTL-699-2 (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07056036?

This trial is sponsored by BTL Industries, which has 9 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07056036 being conducted?

This trial has 4 study locations across Colorado, Florida, Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial